EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›STXS

STXS

Stereotaxis, Inc.

Next earnings Aug 3, 2026 (after close) · consensus $-0.05 EPS, $8.52M rev

Last earnings +2.1% on 2026-05-12

Sell
$1.68
▲ +3.70%
$1.68▼ -20.38%
over 1Y
L $1.62EODHDH $3.57
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.7%
1W-10.2%
1M-16.4%
3M-7.7%
YTD-27.6%
1Y-20.4%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
C-
Valuation
Fair value
Filings
Flagged
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Buy

Revenue grew 20.3% YoY; but unprofitable (net margin -66.8%).

Revenue (FY2025) $32.4M · FY2025

Stereotaxis, Inc. shows $32.4M in FY2025 revenue (+20.3% YoY), a -66.8% net margin, and -160.5% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$35.0M$28.1M$26.8M$26.9M$32.4M
Gross profit$23.2M$18.5M$14.9M$14.6M$17.1M
Operating income-$12.9M-$18.8M-$21.8M-$24.7M-$22.1M
Net income-$10.7M-$18.3M-$20.7M-$24.0M-$21.6M
Diluted EPS-$0.16-$0.26-$0.27-$0.30-$0.25
Net margin-30.6%-65.0%-77.4%-89.3%-66.8%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$152M
EV / EBITDA—
EV / Sales4.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-13.2%
FCF yield-8.4%

Quality & risk

ROIC (est.)-111.7%
Free cash flow-$13.8M
Total debt$2.16M
Net cash$11.3M
Altman Z-Score-13.22 distress
Piotroski F-Score5/9

Capital returns

Buyback yield—
Dividend yield (est.)0.0%
Shareholder yield0.0%
Shares Δ YoY+13.1%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-04-03). Worth a closer look.
  1. 8-K Shareholder vote2026-05-15
  2. 10-Q Quarterly report2026-05-13
  3. 8-K Earnings results2026-05-12
  4. 8-K Material agreement2026-04-15
  5. 10-K/A Restated periodic report2026-04-03
  6. DEF 14A Proxy statement2026-04-03
  7. S-3 Shelf registration (potential raise)2026-03-13
  8. 10-K Annual report2026-03-12
  9. 8-K Earnings results2026-03-09

Recent filings

all on EDGAR ↗
SDFiling2026-05-29open ↗SCHEDULE 13G/AFiling2026-05-15open ↗8-KPeriod ending 2026-05-142026-05-15open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-122026-05-12open ↗8-KPeriod ending 2026-04-142026-04-15open ↗4Period ending 2026-04-112026-04-13open ↗10-K/APeriod ending 2025-12-312026-04-03open ↗DEFA14AFiling2026-04-03open ↗DEF 14APeriod ending 2026-04-032026-04-03open ↗EFFECTFiling2026-03-20open ↗CORRESPFiling2026-03-18open ↗

Quality score

C-
ValueGrowthProfitHealthMom.
ValueC
GrowthB+
ProfitabilityF
Financial healthC
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
Revenue
$32.4M
+20.3% YoY
Net margin
-66.8%
ROE
-160.5%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$32.4M+20.3%
Net income-$21.6M+10.0%
Gross profit$17.1M+17.0%
Operating income-$22.1M+10.6%
Diluted EPS-$0.25+16.7%
Cash & equivalents$13.4M+9.9%
Total assets$52.3M+11.8%
Total liabilities$33.5M-5.0%
Stockholders' equity$13.5M+121.7%
Gross: 52.7%Op.: -68.3%L/E: 2.49x

Frequently asked

Is Stereotaxis, Inc. (STXS) a buy?
STXS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 20.3% YoY; but unprofitable (net margin -66.8%).
What is Stereotaxis, Inc.'s quality score?
STXS scores 50.686274509803916/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001289340, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 4:41:46 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-01-02
Menawat Arun Swarup
Director
Award46.9K
2026-01-02
Benfer David
Director
Award46.9K
2026-01-02
Curet Myriam
Director
Award46.9K
2026-01-02
Fischel Nathan
Director
Award46.9K
2026-01-02
Levin Ross B
Director
Award46.9K
2026-01-02
SHAMIR NACHUM
Director
Award46.9K
2025-11-17
Isaac Paul J
Director
Buy10.0K @ $2.18$21.8K
2025-11-14
Isaac Paul J
Director
Buy20.0K @ $2.24$44.8K

Earnings history

beat/miss · move
2026-05-12Miss -19.5% est▲ +2.13%8-K ↗
2026-03-09Beat +10.0% est▲ +0.98%8-K ↗
2025-11-12Miss -14.4% est▼ -14.74%8-K ↗
2025-08-07Beat +24.6% est▼ -2.67%8-K ↗
2025-07-17Beat +24.6% est▼ -0.42%8-K ↗
2025-05-12—▼ -2.82%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
ISRG's Capital Placement Surge: Demand Strength or Upgrade Cycle Peak?Bullish
finance.yahoo.com· 2026-06-15
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?Bullish
finance.yahoo.com· 2026-05-25
Analysts See 124.7% Upside In Stereotaxis (STXS); Find Out WhyBullish
finance.yahoo.com· 2026-05-24
Stereotaxis expects annual revenue to surpass $40M with Q3 and Q4 above $10M as MAGiC and Synchrony rampBullish
seekingalpha.com· 2026-05-13
Stereotaxis Reports 2026 First Quarter Financial Results & Business UpdatesBullish
globenewswire.com· 2026-05-12
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue EstimatesBullish
finance.yahoo.com· 2026-05-05

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score51 vs 67
Revenue growth20.3% vs 7.1%
Net margin-66.8% vs 10.5%
Return on equity-160.5% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 6d
Bullish
+0.11
vs typical · 6 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.